Welcome to our dedicated page for Larimar Therapeutics news (Ticker: LRMR), a resource for investors and traders seeking the latest updates and insights on Larimar Therapeutics stock.
Larimar Therapeutics, Inc. (NASDAQ: LRMR) is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, with its lead compound, nomlabofusp, in development as a potential treatment for Friedreich’s ataxia (FA). The Larimar news feed on Stock Titan aggregates the company’s press releases and related coverage so readers can follow key milestones in this rare disease program.
News about Larimar frequently centers on clinical data updates from the ongoing long-term open-label and open-label extension studies of nomlabofusp in FA. The company has reported increases in skin frataxin (FXN) levels with daily subcutaneous dosing, directional improvements in clinical outcome measures such as mFARS, FARS-ADL, 9-Hole Peg Test, and Modified Fatigue Impact Scale, and long-term safety observations including injection site reactions and anaphylaxis events. Larimar also publishes nonclinical findings that describe the mechanism of action and pharmacology of nomlabofusp as an FXN protein replacement therapy.
Another major category of LRMR news involves regulatory interactions and timelines. Larimar has disclosed written recommendations from the U.S. Food and Drug Administration on the safety database needed for its Biologics License Application and the agency’s openness to using skin FXN concentrations as a reasonably likely surrogate endpoint for an accelerated approval pathway. The company regularly issues press releases on these regulatory updates, its participation in the START pilot program, and its targeted timing for a BLA submission seeking accelerated approval.
Investors and followers will also see financial results and capital markets announcements, including quarterly operating and financial updates, underwritten public offerings of common stock, and the use of proceeds to fund nomlabofusp development and other pipeline plans. For a consolidated view of LRMR-related developments—spanning clinical, regulatory, and financing events—this news page provides an organized stream of Larimar’s own disclosures and market-facing communications.
Larimar Therapeutics (Nasdaq:LRMR) reported its Q3 2020 results, showcasing progress in clinical trials and financial stability. The Phase 1 trials for CTI-1601, aimed at treating Friedreich’s ataxia, are set to deliver topline data in 1H 2021 following delays due to COVID-19. The company holds $102.3 million in cash and equivalents. Despite a net loss of $10.3 million, down from $8.6 million year-over-year, R&D expenses decreased to $6.9 million. The European Commission granted CTI-1601 orphan drug designation, enhancing regulatory support.
LARIMAR Therapeutics (Nasdaq:LRMR) announced the establishment of its Scientific Advisory Board (SAB) on October 13, 2020. The SAB includes leading experts in rare diseases and mitochondrial disorders, aiming to advance the development of CTI-1601 for Friedreich’s ataxia. The company has resumed its Phase 1 clinical trial for this treatment and received a favorable orphan drug opinion from the European Medicines Agency. The presence of distinguished advisors is expected to bolster Larimar's strategic direction in addressing complex rare disease treatment needs.
Larimar Therapeutics (Nasdaq: LRMR), a clinical-stage biotechnology company, announced that CEO Carole Ben-Maimon will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21, 2020, at 1:40 p.m. EDT. The company focuses on developing treatments for complex rare diseases, with its lead compound CTI-1601 currently in Phase 1 clinical trials aimed at addressing Friedreich’s ataxia. Larimar intends to utilize its intracellular delivery platform to create additional fusion proteins targeting other rare diseases.
Larimar Therapeutics (Nasdaq:LRMR) announced that its CEO, Carole Ben-Maimon, MD, will participate in the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 17, 2020, at 11:45 a.m. EDT. A live audio webcast of the event will be available on the company's website, with an archived version available for 30 days afterward.
The company focuses on developing treatments for complex rare diseases, with its lead compound, CTI-1601, currently in a Phase 1 clinical program targeting Friedreich’s ataxia.
Larimar Therapeutics, Inc. (Nasdaq:LRMR) has announced significant advancements following its merger with Chondrial and Zafgen, including a completed $80 million private placement financing. The company has resumed its Phase 1 clinical trial for CTI-1601, targeting Friedreich’s ataxia, and received a positive opinion for orphan drug designation from the EMA. In the second quarter of 2020, Larimar reported a net loss of $11.3 million, with R&D expenses rising to $8.9 million due to increased development activities. The company holds approximately $113.7 million in cash and equivalents.
Larimar Therapeutics (Nasdaq:LRMR) has initiated the third cohort dosing in its Phase 1 clinical trial for CTI-1601, targeting Friedreich’s ataxia (FA). The trial, which encountered delays due to COVID-19, aims to assess the safety and tolerability of this recombinant fusion protein. To date, two cohorts have completed the trial, with topline results expected in early 2021. CTI-1601 has received multiple FDA designations, underscoring its potential as the first frataxin replacement therapy for FA, which currently has no approved treatments.
Larimar Therapeutics, Inc. (Nasdaq:LRMR) announced that Dr. Carole Ben-Maimon, President and CEO, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 4:30 p.m. EDT. The presentation will focus on the company’s advancements in developing treatments for complex rare diseases such as Friedreich’s ataxia. Interested investors can access a live audio webcast from the Investors section of Larimar’s website, which will also feature an archived version available for 30 days post-event.